Integrative Oncology: What 44 Specialist Practitioners Recommend for Cancer Recovery

Standard oncology treats cancer as a tumour to be destroyed. Forty-four integrative oncology specialists across medicine, naturopathy, immunology, and functional medicine describe a different picture: cancer as a whole-body terrain failure, where immune suppression, metabolic dysfunction, chronic stress, toxic accumulation, and nutritional deficiencies combine to create the conditions in which cancer cells develop and persist. The clinical prescriptions that follow from this understanding are specific, mechanistic, and substantially different from what most patients are told is available to them.

• The immune system, not the tumour, is the primary therapeutic target in integrative oncology.
• Chronic stress, unresolved trauma, and sympathetic nervous system dominance suppress the immune surveillance that normally prevents cancer from establishing.
• Genetic variants in detoxification enzymes, hormone metabolism, and nutrient processing explain wide variation in cancer risk, chemotherapy tolerance, and treatment response.
• Specific interventions, including IV therapies, frequency medicine, dietary protocols, and emotional processing practices, address distinct biological mechanisms and are most effective when matched to individual terrain factors.
• Dental health, lymphatic flow, and post-treatment recovery are consistently under-addressed in standard oncology and consistently present as contributing factors in integrative assessments.
• Prevention is a more powerful strategy than any treatment: the same terrain factors that produce cancer are modifiable years before clinical diagnosis.

The terrain model and why it changes everything

The central argument across all 44 practitioners is that cancer is not primarily a genetic accident. Research cited by multiple contributors places hereditary cancer at roughly 5 to 7 percent of all cases. The remaining 90-plus percent arises from the interaction between genetic susceptibilities and the cellular environment those genes are expressed in. Epigenetics, the science of gene activity regulation without changes to the DNA sequence itself, provides the mechanism: the same gene variant that produces disease in a high-stress, nutrient-depleted, toxin-burdened body may remain dormant in a body with adequate terrain support.

Dr. Dean Ornish's research demonstrated that changes to diet, lifestyle, environment, and relationships activated 500 genes associated with cellular healing, enhanced immunity, and longevity. The same inputs in reverse can activate cancer-promoting gene expression. This is not theoretical: it has measurable molecular correlates in inflammation markers, hormone levels, immune cell counts, and circulating tumour cell readings.

The practical implication is that identifying and addressing the specific combination of terrain factors driving an individual's cancer is as clinically important as selecting a treatment protocol. Two patients with identical diagnoses may have entirely different primary drivers: heavy metal toxicity from dental amalgam, chronic sympathetic nervous system activation from unresolved trauma, or inherited impairment of the cytochrome P450 detoxification enzymes that clear both carcinogens and chemotherapy agents.

How the immune system controls cancer and what suppresses it

All humans carry cancer cells. A functioning immune system continuously identifies and eliminates them through natural killer cells, T cells, and dendritic cells before they accumulate to detectable disease. Cancer develops when immune surveillance fails, not simply when cancer cells appear.

The most consistently identified cause of immune suppression across the 44 practitioners is chronic psychological stress. Stress activates the sympathetic nervous system (the fight-or-flight response), which suppresses natural killer cell activity, reduces lymphocyte production, and promotes the pro-inflammatory cytokine signalling that creates a cancer-permissive cellular environment. Acute stress is recoverable; chronic stress, whether from financial pressure, relationship dysfunction, occupational dissatisfaction, or unresolved trauma that remains physiologically active years after the original event, produces sustained immune downregulation with no natural recovery period.

T regulatory cells (Treg cells) add a second layer of complexity. These immune cells calibrate the balance between inflammatory response and targeted immune activity. When Treg cells are underactive, the immune system produces a chronic pro-inflammatory state characterised by elevated circulating cytokines. This state is not immune activation against cancer: it simultaneously promotes tumour microenvironment formation and fails to perform effective cancer cell surveillance. Vitamin D3 at serum levels of 80 to 90 ng/mL is identified by multiple practitioners as a primary regulator of Treg function, which explains its consistent presence across integrative oncology protocols regardless of cancer type.

Metabolic approaches: ketogenic diet, fasting, and the Warburg effect

Nobel Prize-winning biochemist Dr. Otto Warburg demonstrated in the 1920s that cancer cells preferentially ferment glucose for energy even when oxygen is available, rather than using the more efficient aerobic pathway that normal cells use. This metabolic dependency is visible on PET scans, where cancer tissue appears prominently because it absorbs radioactively labelled glucose far more actively than surrounding normal tissue.

Ketogenic diet (a very low carbohydrate, high fat dietary pattern in which the liver produces ketone bodies as an alternative fuel) exploits this asymmetry. Normal cells are metabolically flexible and can transition between glucose and ketone metabolism. Cancer cells, which have lost much of this flexibility through mitochondrial dysfunction, are selectively disadvantaged when blood glucose is reduced. Surgical data from the Barrow Neurological Institute in Phoenix showed that glioblastoma patients already in ketosis at the time of surgery consistently had better surgical outcomes and faster recovery than those who were not.

Reducing blood glucose also lowers circulating insulin and insulin-like growth factor 1 (IGF-1), both of which directly stimulate cell proliferation through the PI3K-AKT-mTOR signalling pathway. This pathway is overactivated in most cancers and is a target of multiple pharmaceutical agents. Metabolic dietary interventions reduce its activity through the same pathway without pharmaceutical agents.

Intermittent fasting and time-restricted eating amplify these effects and activate autophagy (a cellular self-cleaning process in which cells break down and recycle damaged components, including pre-cancerous cells). A study of patients with upper gastrointestinal cancers found that two years of resistant starch supplementation produced a roughly 60 percent reduction in colorectal cancer prevalence, and the protective effect persisted for a decade after the study ended.

Genetic testing and personalised protocol design

One of the most clinically significant contributions of integrative oncology is the use of genetic testing to personalise both prevention and treatment protocols. Variants (SNPs, or single nucleotide polymorphisms) in specific genes determine how efficiently an individual detoxifies carcinogens, metabolises hormones, converts dietary nutrients to usable forms, and tolerates chemotherapy.

The cytochrome P450 enzymes (phase 1 liver detoxification) convert toxic compounds and chemotherapy agents into intermediate forms for excretion. Patients with slow-functioning P450 variants accumulate chemotherapy metabolites more rapidly, producing severe side effects at doses that other patients tolerate without difficulty. Identifying these variants and supporting the relevant pathways with targeted nutrients before and during treatment allows these patients to receive therapeutic benefit while reducing toxicity. The MTHFR gene affects folate metabolism and methylation (a chemical process governing gene expression and DNA repair), with variants present in a significant proportion of the population that impair the body's ability to process certain nutrients and detoxify specific compounds.

Polygenic risk scores, which aggregate multiple low-impact variants to estimate overall cancer susceptibility, are beginning to inform preventive strategies decades before any clinical signs appear. Several practitioners describe discovering their own high-risk profiles through genetic testing and using that knowledge to implement targeted prevention protocols rather than waiting for symptoms.

IV therapies and frequency medicine

Several IV treatments are described across the 44 practitioners as having specific, mechanistically explained anti-cancer activity beyond what oral supplementation can achieve.

High-dose intravenous vitamin C, at concentrations achievable only through IV administration, acts as a pro-oxidant in the cellular environment. It generates hydrogen peroxide preferentially in cancer cells, which lack the catalase enzyme activity to neutralise it. Normal cells retain this protective capacity. The result is selective cytotoxicity against cancer cells at doses that are well tolerated by normal tissue.

IV curcumin (an emulsified preparation of the active compound in turmeric, formulated for intravenous safety) has demonstrated anti-tumour activity across multiple cancer types, with particularly strong evidence in brain cancers. The emulsified formulation is critical: the cyclodextrin alternative produces substantially inferior clinical results, a difference documented through on-off clinical observation when supply chain issues forced temporary substitution.

Rife frequency technology uses light frequencies transmitted through gas-filled Tesla tube devices to stimulate cancer cells at their resonant frequency, triggering local cytokine release and prompting immune re-examination of cells that cancer's surface-protein camouflage mechanisms had previously hidden from surveillance. The mechanism is immune stimulation rather than direct cell destruction. Its effectiveness depends on sufficient immune system capacity to respond, which is why it is used within a supported nutritional and dietary protocol rather than as a standalone treatment.

Dental interference fields, lymphatic health, and overlooked terrain factors

Several practitioners describe categories of terrain factor that receive almost no attention in standard oncology.

Root canal treatments leave a dead tooth in the jaw whose dentinal tubules (microscopic channels in the tooth structure) can be colonised by anaerobic bacteria. The immune system's blood supply cannot reach these tubules effectively, meaning chronic low-grade bacterial infection can persist for years, continuously releasing biotoxins into the bloodstream. In Chinese medicine's meridian mapping of organ-tooth relationships, the upper molars sit on the meridian pathway running through the breast and prostate. Multiple practitioners describe clinically consistent patterns of breast cancer patients with root canal treatments in these specific teeth.

Mercury amalgam dental fillings release mercury vapour continuously through normal chewing and temperature changes. Improper removal, using standard high-speed drilling technique, releases a large acute bolus of mercury vapour that can trigger autoimmune conditions and neurological damage. Proper removal requires a biological dentist using the SMART protocol (Safe Mercury Amalgam Removal Technique), rubber dam isolation, and high-volume suction.

The lymphatic system, the body's drainage and immune transport network, has no central pump and depends entirely on movement, breathing, and muscular contraction to circulate fluid. It is the route through which immune cells reach tissues and through which cellular waste is cleared. Lymphatic congestion, observable through computerised regulation thermography (a functional scan using 120 temperature measurement points and a mild cold stress test), consistently precedes breast cancer development by years to over a decade. Physical constriction from tight clothing, magnesium deficiency, and physical inactivity all contribute to lymphatic stagnation.

The stress-emotion-immune connection and what practitioners prescribe

Psychoneuroimmunology, the scientific field studying how psychological states influence immune and neurological function through measurable molecular pathways, was established by Dr. Robert Ader in the 1960s and has generated decades of research demonstrating that unresolved emotional trauma produces chronic neurochemical and hormonal patterns that alter immune function, gene expression, and inflammatory tone in the specific ways that create cancer-permissive biological conditions.

Unprocessed emotional experiences are not merely psychologically uncomfortable. They maintain chronic patterns of neuropeptide signalling (neuropeptides are small protein molecules produced by neurons that regulate immune function and cellular behaviour throughout the body) that produce persistent low-grade inflammation. Several practitioners describe this as the single most consistently overlooked factor in patients who implement every physical health intervention but continue to develop or fail to resolve cancer.

Practical interventions prescribed across the 44 practitioners include daily meditation and parasympathetic activation practices, trauma-informed therapy, forgiveness work, community connection, and the identification of meaningful goals or purpose that engage the patient's neurological and motivational systems beyond treatment compliance. These are not adjuncts to the clinical protocol. They are the foundational conditions that determine whether the physical protocol can produce its intended effects, because the immune system operates at full capacity only in the parasympathetic (rest-and-repair) state.

Where these ideas come from

The ideas in this section of the knowledge base originate from the work of Zonia, specifically the docuseries Cancer 360: Unravel Cancer and Reclaim Your Health, available through the Zonia platform. The series brings together 44 named specialist practitioners across integrative oncology, functional medicine, naturopathy, immunology, Ayurvedic medicine, and related disciplines, each presenting their clinical frameworks and protocols across 97 episodes. The breadth of practitioner expertise and the clinical specificity of the material make it an unusually dense resource for understanding the full scope of integrative cancer care. If you want to experience the original work in full, it is well worth seeking out directly.

The knowledge base itself is an independent work. Every concept has been studied, rewritten from scratch, and restructured for use in a multi-source advisory system. Nothing from the original has been reproduced. The knowledge has been transformed, not copied. The source is named clearly because the ideas deserve proper credit, and because the original work stands on its own merits.